Loading...
NPI 1134873649 · Jackson, MS · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Srs 2 LLC is a clinical medical laboratory provider located in Jackson, Mississippi. This profile covers 5 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Srs 2 LLC |
| Address | 235 W Lorenz Blvd |
| City | Jackson |
| State | MS |
| ZIP | 39213 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 4, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.2M |
| Medicaid | $1.8M |
SRS 2 LLC (Clinical Medical Laboratory) in JACKSON, MS has been NPI-enumerated since 2022-02-04 (~4 years ago), indicating a recent market entry compared with longer-established laboratories. Its declared practice taxonomy and the detailed CPT/HCPCS mix show an operational focus on diagnostic laboratory work rather than outpatient clinical services.
The provider’s Medicare business is overwhelmingly concentrated in a single code: K1034 accounts for $5.2M of the provider’s Medicare revenue and represents 99.3% of its Medicare revenue. Precomputed figures show the top three Medicare codes together account for 99.8% of Medicare revenue, indicating extreme revenue concentration in a narrow set of COVID-19 test-related services.
On Medicare K1034, SRS 2 LLC is a national high-volume outlier: it ranks #89 of 30143 providers nationally (100th percentile; extreme outlier), far above typical national volume for this code. Other Medicare lab codes reported (U0003, U0005, 87635, G2023) together contribute only a small fraction of Medicare revenue and mostly reflect modest, typical participation by rank and percentile.
The Medicaid footprint is substantial but smaller than Medicare: total Medicare revenue is $5.2M compared with total Medicaid revenue of $1.8M, so Medicare is the larger payer in absolute terms for this entity. Medicaid revenue is likewise concentrated in COVID-19 testing and specimen collection codes, with the top three Medicaid codes accounting for 95.1% of Medicaid revenue.
SRS 2 LLC is a dominant in-state provider for core Medicaid testing codes: U0003 contributes $1.1M and 59.7% of Medicaid revenue and ranks #1 of 56 providers in-state (100th percentile; extreme outlier). U0005 ($379.4K, 20.9%) and G2023 ($264.2K, 14.5%) also rank #1 in-state (100th percentile; extreme outlier each), together establishing state-level leadership in nucleic acid testing and specimen collection for SARS-CoV-2.
The code mix (K1034 nonprescription self-administered COVID-19 test provisioning; U0003/U0005 nucleic acid detection; G2023 specimen collection; 87635 amplified probe detection) signals an operation centered on high-volume COVID-19 testing and test distribution/logistics rather than broad laboratory panels or chronic disease testing. High claim counts for rapid/point-of-care and high-throughput test codes in Medicaid suggest both specimen processing and widespread test provisioning activities.
There is notable payer-concentration and service concentration risk: with Medicare revenue driven 99.8% by the top three codes and Medicaid revenue driven 95.1% by its top three, the business is highly dependent on a small set of COVID-19 testing codes and related specimen-collection services. This concentration implies that reimbursement or policy changes affecting these specific codes could materially affect revenue.
Beyond the extreme outlier positions on K1034 nationally and U0003/U0005/G2023 in-state, other reported code ranks are typical or modest: Medicare U0003 and U0005 are in the middle percentiles nationally (65th and 62nd percentiles respectively), and Medicaid 87635 is a 90th-percentile in-state performer. Those secondary positions indicate the provider’s extraordinary scale is tightly focused on a few pandemic-era testing services rather than a broad, diversified lab portfolio.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 437,320 | $10 | $5.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 250 | $70 | $18.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 250 | $30 | $6.2K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 120 | $50 | $6K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 250 | $20 | $5.7K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 54,210 | $20 | $1.1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 54,200 | $10 | $379.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 14,680 | $20 | $264.2K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 3,580 | $20 | $78.7K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 300 | $20 | $6K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 70 | $50 | $3.5K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 890 | $1 | $890 |
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 10 | 20 | 60 | $100 | $124.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 60 | 190 | $40 | $111.1K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 233 | 440 | 380 | $30 | $49.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 27 | 250 | 270 | $30 | $41.8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1 | 40 | 210 | $10 | $31.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1 | 70 | 320 | $10 | $14.6K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1 | 10 | 230 | $1 | $570 |
Other providers in the same ZIP code as Srs 2 LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.